MRS2 and metabolic dysfunction-associated steatohepatitis: There was no significant difference in Fuc-Hpt levels between normal control and non-NASH patients (167.8±211.0 vs. 111.1±202.1 U/mL, P = 0.221) (Table 1, Fig. 1A).